Year: 2025

Fiscal Q2 2026 (which began on Aug 1, 2025 and ended Oct 31, 2025) included a $500M private placement, fueling BNC’s digital assets treasury transformation. World’s Largest BNB Treasury with over 500,000 BNB held, providing unmatched exposure to a leading digital asset ecosystem.LOUISVILLE, CO, Dec. 15, 2025 (GLOBE NEWSWIRE) — CEA Industries Inc. (NASDAQ: BNC), (“BNC” or the “Company”), today reported financial results for its second fiscal quarter ended October 31, 2025. “This quarter marked the definitive transformation into our new identity as BNC,” said David Namdar, CEO of CEA Industries. “By closing a $500 million financing round, launching our new ticker, and rapidly accumulating over 500,000 BNB tokens, we have successfully laid the foundation for our DAT strategy. With a strengthened Board of Directors, a launched...

Holders will have until December 30, 2025 to exercise Tranche A Warrants at $1.05 per share, enabling up to $17.9 million in potential gross proceeds BURLINGTON, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) — Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company” or “Fractyl”), a metabolic therapeutics company focused on pioneering pattern-breaking approaches that treat root causes of obesity and type 2 diabetes (“T2D”), today announced that it will call all of its outstanding Tranche A Common Stock Purchase Warrants (the “Tranche A Warrants”) to purchase shares of the Company’s common stock, par value $0.00001 per share (the “Common Stock”) for cancellation for cash consideration of $0.00001 per underlying share at 6:30 p.m., New York City time, on December 30, 2025 (the “Cancellation Date”). The Tranche A Warrants were issued in connection...

Arbitration Ruling Reaffirms Allogene’s Full Control of Cemacabtagene Ansegedleucel (Cema-Cel) Decision Reconfirms Allogene’s Expanded Sub-License Covering EU and UK Rights with Options for Japan and China, Clearing the Path for Allogene to Acquire Full Global Rights 1H 2026 Interim Futility Analysis from the Pivotal Phase 2 ALPHA3 Trial with Cema-Cel in First-Line (1L) Consolidation Large B-Cell Lymphoma (LBCL) Remains on TrackSOUTH SAN FRANCISCO, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today noted the favorable outcome for Servier in its arbitration with Cellectis (Euronext Growth: ALCLS –  NASDAQ: CLLS) as it relates to cemacabtagene ansegedleucel...

Phoenix, AZ, Dec. 15, 2025 (GLOBE NEWSWIRE) — InnSuites Hospitality Trust (NYSE American: IHT) reported Hotel Revenue results surpassing $5.8 million once again in the First Three Fiscal Quarters of 2026, (February 1, 2025, to October 31, 2025), with Total Revenue of approximately $5,809,673. Consolidated Net Income before the non-cash expense of depreciation and the non-cash Best Western Rewards Guest Vouchers expense, was approximately break-even at (-48,000), for the 2026 First Fiscal Three Quarters ended October 31, 2025 (February 1, 2025, through October 31, 2025). IHT hotel operations were strong in the 2025 Fiscal Year ended January 31, 2025, and are contributing to a comparable 2026 Fiscal Year. Combined Hotel November Revenue for both hotels was the second highest combined November amount of approximately $550,000, which...

ST. PETERSBURG, Fla., Dec. 15, 2025 (GLOBE NEWSWIRE) — BayFirst Financial Corp. (NASDAQ: BAFN) (“BayFirst” or the “Company”), parent company of BayFirst National Bank (the “Bank”) today announced it has closed its planned loan sale to Banesco USA. “I am pleased to announce BayFirst has closed on the sale of $94.6 million of loans to Banesco USA. We announced this transaction on September 29, 2025, as part of a comprehensive strategic review aimed at derisking SBA 7(a) balances on the balance sheet and positioning the Company for long-term growth and enhanced shareholder value. On a proforma basis, the Bank’s total capital ratio improves to 10.1% and the tier 1 leverage ratio improves to 6.8%,” stated Thomas G. Zernick, Chief Executive Officer. “As we previously announced, BayFirst exited the SBA 7(a) lending business early in the...